Arcus Biosciences, Inc.

For the period ended Jun 30, 2025. Filed Aug 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 6, 2025

RCUS$18.95+3.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(In millions, except per share amounts)

	Three Months EndedJune 30,		Six Months EndedJune 30,
	2025	2024	2025	2024
Revenues:
License and development services revenue (Includes $152, $25, $172 and $156 from a related party)	$152	$28	$172	$163
Other collaboration revenue (Includes $8, $11, $16 and $21 from a related party)	8	11	16	21
Total revenues	160	39	188	184
Operating expenses:
Research and development (Includes $11, ($14), $6 and ($30) from a related party)	139	115	261	224
General and administrative (Includes $2, $—, $2, and $— from a related party)	29	30	57	62
Impairment of long-lived assets (see Note 12, Leases)	—	—	—	20
Total operating expenses	168	145	318	306
Loss from operations	(8)	(106)	(130)	(122)
Non-operating income (expense):
Interest and other income, net	10	13	21	26
Interest expense	(2)	—	(3)	(1)
Total non-operating income, net	8	13	18	25
Income (loss) before income taxes	—	(93)	(112)	(97)
Income tax expense	—	—	—	—
Net income (loss)	$—	$(93)	$(112)	$(97)
Net income (loss) per share:
Basic	$—	$(1.02)	$(1.09)	$(1.09)
Diluted	$—	$(1.02)	$(1.09)	$(1.09)
Shares used to compute net income (loss) per share:
Basic	106.1	91.1	102.3	88.6
Diluted	106.5	91.1	102.3	88.6

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.